These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 38061448)

  • 1. NIS2+
    Ratziu V; Harrison SA; Hajji Y; Magnanensi J; Petit S; Majd Z; Delecroix E; Rosenquist C; Hum D; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2024 Feb; 80(2):209-219. PubMed ID: 38061448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH.
    Anstee QM; Magnanensi J; Hajji Y; Caron A; Majd Z; Rosenquist C; Hum DW; Staels B; Connelly MA; Loomba R; Harrison SA; Ratziu V; Sanyal AJ
    JHEP Rep; 2024 Apr; 6(4):101011. PubMed ID: 38463540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation study.
    Harrison SA; Ratziu V; Magnanensi J; Hajji Y; Deledicque S; Majd Z; Rosenquist C; Hum DW; Staels B; Anstee QM; Sanyal AJ
    J Hepatol; 2023 Sep; 79(3):758-767. PubMed ID: 37224923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NIS2+™, an effective blood-based test for the diagnosis of at-risk nonalcoholic steatohepatitis in adults 65 years and older.
    Sanyal AJ; Magnanensi J; Majd Z; Rosenquist C; Vera DM; Almas JP; Connelly MA
    Hepatol Commun; 2023 Sep; 7(9):. PubMed ID: 37556372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FibroScan-aspartate transaminase: A superior non-invasive model for diagnosing high-risk metabolic dysfunction-associated steatohepatitis.
    Yin JY; Yang TY; Yang BQ; Hou CX; Li JN; Li Y; Wang Q
    World J Gastroenterol; 2024 May; 30(18):2440-2453. PubMed ID: 38764767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes.
    Castera L; Garteiser P; Laouenan C; Vidal-Trécan T; Vallet-Pichard A; Manchon P; Paradis V; Czernichow S; Roulot D; Larger E; Pol S; Bedossa P; Correas JM; Valla D; Gautier JF; Van Beers BE;
    J Hepatol; 2024 Aug; 81(2):195-206. PubMed ID: 38548067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study.
    Kouvari M; Valenzuela-Vallejo L; Guatibonza-Garcia V; Polyzos SA; Deng Y; Kokkorakis M; Agraz M; Mylonakis SC; Katsarou A; Verrastro O; Markakis G; Eslam M; Papatheodoridis G; George J; Mingrone G; Mantzoros CS
    Metabolism; 2023 Oct; 147():155666. PubMed ID: 37527759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FIB-4 as a screening and disease monitoring method in pre-fibrotic stages of metabolic dysfunction-associated fatty liver disease (MASLD).
    Albert SG; Wood EM
    J Diabetes Complications; 2024 Jul; 38(7):108777. PubMed ID: 38788522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.
    Marti-Aguado D; Arnouk J; Liang JX; Lara-Romero C; Behari J; Furlan A; Jimenez-Pastor A; Ten-Esteve A; Alfaro-Cervello C; Bauza M; Gallen-Peris A; Gimeno-Torres M; Merino-Murgui V; Perez-Girbes A; Benlloch S; Pérez-Rojas J; Puglia V; Ferrández-Izquierdo A; Aguilera V; Giesteira B; França M; Monton C; Escudero-García D; Alberich-Bayarri Á; Serra MA; Bataller R; Romero-Gomez M; Marti-Bonmati L
    Liver Int; 2024 Jan; 44(1):202-213. PubMed ID: 37904633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis.
    Charlton M; Tonnu-Mihara I; Teng CC; Zhou Z; Asefaha F; Luthra R; Hoovler A; Uzoigwe C
    J Med Econ; 2024; 27(1):919-930. PubMed ID: 38953706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.
    Mózes FE; Lee JA; Vali Y; Selvaraj EA; Jayaswal ANA; Boursier J; de Lédinghen V; Lupșor-Platon M; Yilmaz Y; Chan WK; Mahadeva S; Karlas T; Wiegand J; Shalimar ; Tsochatzis E; Liguori A; Wong VW; Lee DH; Holleboom AG; van Dijk AM; Mak AL; Hagström H; Akbari C; Hirooka M; Lee DH; Kim W; Okanoue T; Shima T; Nakajima A; Yoneda M; Thuluvath PJ; Li F; Berzigotti A; Mendoza YP; Noureddin M; Truong E; Fournier-Poizat C; Geier A; Tuthill T; Yunis C; Anstee QM; Harrison SA; Bossuyt PM; Pavlides M
    Liver Int; 2024 Aug; 44(8):1872-1885. PubMed ID: 38573034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.
    Sergi CM
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39126031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study.
    Harrison SA; Ratziu V; Boursier J; Francque S; Bedossa P; Majd Z; Cordonnier G; Sudrik FB; Darteil R; Liebe R; Magnanensi J; Hajji Y; Brozek J; Roudot A; Staels B; Hum DW; Megnien SJ; Hosmane S; Dam N; Chaumat P; Hanf R; Anstee QM; Sanyal AJ
    Lancet Gastroenterol Hepatol; 2020 Nov; 5(11):970-985. PubMed ID: 32763196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    ; ;
    Obes Facts; 2024; 17(4):374-444. PubMed ID: 38852583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of non-invasive tests for the detection of significant fibrosis in patients with metabolic dysfunction-associated steatotic liver disease is not superior to magnetic resonance elastography alone.
    Duman S; Kuru D; Gumussoy M; Kiremitci S; Gokcan H; Ulas B; Ellik Z; Ozercan M; Er RE; Karakaya F; Bodakci E; Erden A; Elhan AH; Savas B; Loomba R; Idilman R
    Eur Radiol; 2024 Jun; 34(6):3882-3888. PubMed ID: 37987833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
    ; ;
    J Hepatol; 2024 Sep; 81(3):492-542. PubMed ID: 38851997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
    Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
    J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One-step non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis and fibrosis in high-risk population.
    Iruzubieta P; Mayo R; Mincholé I; Martínez-Arranz I; Arias-Loste MT; Ibañez-Samaniego L; Ampuero J; Abad J; Martín-Mateos R; Fernández-Laso AB; Albillos A; Bañares R; Calleja JL; Romero-Gómez M; Aller R; Crespo J
    United European Gastroenterol J; 2024 Sep; 12(7):919-929. PubMed ID: 39099245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
    Vuppalanchi R; Loomba R; Sanyal AJ; Nikooie A; Tang Y; Robins DA; Brouwers B; Hartman ML
    Aliment Pharmacol Ther; 2024 Jul; 60(1):17-32. PubMed ID: 38768298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD): Executive Summary.
    ; ;
    Diabetologia; 2024 Nov; 67(11):2375-2392. PubMed ID: 38869512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.